Cellectar Biosciences EBITDA 2010-2024 | CLRB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cellectar Biosciences ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cellectar Biosciences ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$204.2B
Stryker (SYK)	$146.7B
Boston Scientific (BSX)	$132.6B
EssilorLuxottica (ESLOY)	$112.1B
Medtronic (MDT)	$110.6B
Haleon (HLN)	$43.7B
Lonza Group Ag (LZAGY)	$42.2B
GE HealthCare Technologies (GEHC)	$37.7B
ResMed (RMD)	$35.8B
Terumo (TRUMY)	$29.7B
Koninklijke Philips (PHG)	$24.8B
Zimmer Biomet Holdings (ZBH)	$21.9B
Insulet (PODD)	$18.4B
Baxter (BAX)	$17B
Smith & Nephew SNATS (SNN)	$11.1B
BellRing Brands (BRBR)	$10.2B
Bio-Rad Laboratories (BIO)	$9.3B
Demant (WILYY)	$8.3B
Lantheus Holdings (LNTH)	$6.3B
TG Therapeutics (TGTX)	$5.5B
Haemonetics (HAE)	$4.3B
Prestige Consumer Healthcare (PBH)	$4.2B
ICU Medical (ICUI)	$4.1B
Perrigo (PRGO)	$3.8B
Envista Holdings (NVST)	$3.7B
Neogen (NEOG)	$3.2B
Agios Pharmaceuticals (AGIO)	$3.2B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.8B
QuidelOrtho (QDEL)	$2.7B